2000至2020年美国多发性骨髓瘤成人患者接受化疗和/或免疫治疗后的生存时间趋势
该研究基于美国人群数据,纳入2000至2019年诊断并接受初始化疗和/或免疫治疗的50 288例多发性骨髓瘤成人患者,评估总生存(OS)随时间的变化及人口学差异。结果显示OS随时间显著改善,但老年、男性、黑人、西班牙裔、太平洋岛裔及居住于低收入县的患者生存仍较差。
要点
- 2000至2019年接受初始化疗和/或免疫治疗的多发性骨髓瘤成人OS随时间显著改善。
- 2015至2019年较2000至2004年死亡风险降低(HR=0.56,95%CI 0.54-0.58)。
- 老年、男性、黑人、西班牙裔、太平洋岛裔及低收入县患者生存仍较差。
核心结论
- 尽管多发性骨髓瘤患者接受初始化疗和/或免疫治疗后生存持续显著改善,但老年、男性、黑人、西班牙裔、太平洋岛裔及居住于低收入县的患者仍存在未满足的医疗需求。
研究设计与样本
- 基于美国人群的研究,纳入2000至2019年诊断并报告接受初始化疗和/或免疫治疗的50 288例多发性骨髓瘤成人患者。
- 采用多变量Cox回归计算风险比(HR),比较不同日历年时段及患者人口学组内的总生存(OS)。
主要发现
- OS随时间改善:以2000-2004为参照,2005-2009年HR=0.77(95%CI 0.75-0.79),2010-2014年HR=0.65(95%CI 0.63-0.67),2015-2019年HR=0.56(95%CI 0.54-0.58)。
- 年龄、性别、种族-族裔及县中位家庭收入各组均呈现相似改善趋势。
- 2015-2019年期间女性生存优于男性(男性为参照,HR=0.91,95%CI 0.87-0.96)。
- 2015-2019年期间老年患者死亡风险更高:45-64岁为参照,65-79岁HR=1.69(95%CI 1.59-1.80),≥80岁HR=3.32(95%CI 3.08-3.58)。
- 2015-2019年期间黑人、西班牙裔和太平洋岛裔患者死亡风险高于白人(白人为参照):黑人HR=1.07(95%CI 1.00-1.15),西班牙裔HR=1.08(95%CI 1.00-1.16),太平洋岛裔HR=1.85(95%CI 1.40-2.44);居住于家庭收入<$75 000县的患者死亡风险更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Few population-based studies have rigorously evaluated overall survival (OS) differences among adults treated with chemotherapy and/or immunotherapy (chemo/immunotherapy) for multiple myeloma (MM) during the past two decades when the therapeutic landscape substantially evolved. We evaluated OS among 50 288 adults diagnosed with MM between 2000 and 2019 reported to have received initial chemo/immunotherapy. We calculated hazard ratios (HRs) using multivariable Cox regression to compare OS across calendar periods and within patient demographic groups. OS improved over time (2000-2004 = reference; HR2005-2009 = 0.77, 95% CI = 0.75-0.79; HR2010-2014 = 0.65, 95% CI = 0.63-0.67; HR2015-2019 = 0.56, 95% CI = 0.54-0.58) with a similar pattern across age, sex, racial-ethnic and county-level median household income groups. However, demographic differences were noted within each calendar period and persisted in 2015-2019, with more favourable survival among females (males = reference; HR = 0.91, 95% CI = 0.87-0.96) and consistently higher mortality among older patients (45-64 years = reference; HR65-79 years = 1.69, 95% CI = 1.59-1.80; HR≥80 years = 3.32, 95% CI = 3.08-3.58); Black, Hispanic and Pacific Islander patients (White = reference; HRBlack = 1.07, 95% CI = 1.00-1.15; HRHispanic = 1.08, 95% CI = 1.00-1.16; HRPacific Islander = 1.85, 95% CI = 1.40-2.44); and patients living in counties with household incomes <$75 000. Despite progressive and significant improvement in patient survival following initial chemo/immunotherapy for MM, unmet medical needs persisted among older age groups; males; Black, Hispanic and Pacific Islander patients; and those living in lower income counties.
引用
- Dores GM, Vo JB, Schonfeld SJ, et al. Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000-2020. Br J Haematol. 2025. PMID: 40495370. doi:10.1111/bjh.20192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。